Ultragenyx Pharmaceutical Inc (NAS:RARE)
$ 41.87 -0.74 (-1.74%) Market Cap: 3.48 Bil Enterprise Value: 3.11 Bil PE Ratio: 0 PB Ratio: 24.80 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Barclays Virtual Gene Editing & Therapy Summit Transcript

May 24, 2023 / 12:50PM GMT
Release Date Price: $49.98 (-2.80%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everyone. My name is Gena Wang, and I'm (inaudible) analyst at the Barclays. Welcome to our seventh Gene Editing Gene Therapy Summit Conference. I would like to thank all the participants, investors, companies and especially our event team and corporate access team who made this event possible. With that, I would like to introduce our next presenters, Eric Crombez, Chief Medical Officer, Gene Therapy from Ultragenyx.

Eric, thank you very much for joining us today.

Eric Crombez
Ultragenyx Pharmaceutical Inc. - Chief Medical Officer & Executive VP

Right. Great to be here.

Questions & Answers

Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Yes. So I know last week, we just had the ASGCT, you present quite some update last week. So maybe I would just start with a question on your several gene therapy programs. First one is the DTX401 and GSDIa, so when we look at the ASGCT update a longer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot